MC

Molecular Cancer

Molecular Cancer is an internationally recognized journal focused on how basic cancer research drives advances in cancer prevention, diagnostics, and treatment. It is ranked in the top 25% in the Oncology category of Journal Citation Reports and welcomes submissions of broad interest including target therapies, molecular and cellular biology, genomics, genetics and epigenetics, pathology, and tumor immunology.

Looking to publish in Molecular Cancer? Livewrite integrates seamlessly with Word to help you write, edit, and format faster.

Try Livewrite Now
Subject Oncology
Impact Factor 33.9
Quartile Q1
Open Access Type Open
eISSN 1476-4598
Invitation Only No
Cost Range APC: £3690.00 GBP / $5290.00 USD / €4390.00 EUR, plus VAT or local taxes where applicable.

Submission Instructions

Molecular Cancer accepts the following article types. Click on an article type to view submission instructions.

Research Articles

Cover Letter A cover letter is required. The cover letter must explain why the manuscript should be published, address any issues relating to journal policies, declare any potential competing interests, confirm all authors approved the submission, and confirm the manuscript has not been published or submitted elsewhere.
Abstract A structured abstract is required. Abstract must not exceed 250 words. Abstract must be structured with separate sections. Abstract must include the headings Background, Methods, Results, and Conclusions.
Manuscript Main text should be around 5,000 words including the abstract. Manuscript must include Background, Methods, Results, Discussion, Conclusions, and a Declarations section. Manuscript must include three to ten keywords, a Declarations section with the specified subheadings including 'Not applicable' where relevant, a list of abbreviations if abbreviations are used, and documentation of any Large Language Model use in the Methods or another suitable section.
References References are limited to a maximum of 50. References must follow Vancouver style. Only published articles, clinical trial registration records, and abstracts that are published, in press, or publicly available as preprints may be cited, unpublished abstracts/data/personal communications must be excluded from the reference list, journal abbreviations must follow Index Medicus/MEDLINE, and URLs must be numbered and included in the reference list with full details and access date.
Figures & Tables Research articles must include 4 to 6 figures, not including tables. Figure titles and legends must appear in the main manuscript while figure files are uploaded separately, and tables under one page may be placed in the manuscript whereas larger tables may be placed at the end of the document. Figures discussing tumor-bearing mice must show only isolated tumors, new submissions must not contain images of animals bearing tumors, tumors must be excised and pictured next to a ruler for size comparison, other animal model figures must show full-size images as needed, multi-panel figures must be submitted as single composite files, and tables must not be embedded as figures or spreadsheet files.
Reformat to Molecular Cancer using Livewrite Premium

Reviews

Cover Letter A cover letter is required. Cover letter must explain why the manuscript should be published, address any issues relating to journal policies, declare any potential competing interests, confirm all authors approved the submission, confirm the manuscript has not been published or submitted elsewhere, and name the special issue if applicable.
Abstract A structured abstract is required. Abstract must be 350 words or fewer. Abstract must be structured with Background, Main body, and short Conclusion sections. Abstract must include the headings Background, Main body, and short Conclusion.
Manuscript Manuscript must include Background, Main text, and Conclusions sections, with the main text allowed to use short informative subsections. Manuscript must include three to ten keywords and an Availability of data and materials statement, and declarations for competing interests, authors' contributions, acknowledgements, and funding are also required.
References References must follow Vancouver style. Only published or in-press articles, clinical trial registration records, abstracts, and public preprints may be cited; unpublished abstracts, unpublished data, and personal communications must not appear in the reference list, journal abbreviations must follow Index Medicus/MEDLINE, and URLs must be numbered and listed in full with site title, URL, and access date.
Figures & Tables Figure titles and legends must appear in the main manuscript rather than in the graphic files, tables shorter than one page may be placed within the manuscript, and longer tables may be placed at the end with their intended position cited in the text. Figures must be numbered in order and uploaded in that order, multipanel figures submitted as single composite files, tumor-bearing mice figures limited to isolated tumors, other animal model figures shown full-size as needed, and tables must be numbered sequentially and created as tables rather than embedded as figures or spreadsheet files.
Reformat to Molecular Cancer using Livewrite Premium

Recent Publications

Navigating luminal heterogeneity: etiology-based proteogenomic subtyping for targeted treatment strategies in breast cancer

Ya-Hsuan Chang, Yi-Ju Chen, Zhi-Jie Hong, Yi-Jing Hsiao, Kuen-Tyng Lin, Guo-Shiou Liao, Sheng-Fang Su, Ze-Shiang Lin, Huei-Wen Chen, Chia-Li Han, Eric Sheng-Wen Chen, Yin-Chen Hsu, Yan-Ming Chen, Hao Fang, Hao-Chin Yang, Yan-Si Chen, Chien-Yu Lin, Hsiang-En Hsu, Ching-Hung Lin, Pin-Lian Jiang, Pei-Shan Wu, Ching-Wen Chen, Chen-Ting Hung, Ethan Wu, Wei-Tzu Chiu, Fan-Ni Hsing, Tsai-Pei Liu, Chia-Yu Wang, Yu-Tai Wang, Chang-Wei Yeh, Ki-Hok Liao, Ana I Robles, Henry Rodriguez, Show-Ling Yang, Mien-Chie Hung, Yen-Shen Lu, Hsuan-Yu Chen, Sung-Liang Yu, Jyh-Cherng Yu, Yu-Ju Chen

10.1186/s12943-026-02701-x
View Publication

MiR-494-5p suppresses colorectal cancer metastasis by multi-level targeting of KAT2B, a novel mechanism disrupting KAT2B enhancer-promoter looping, and inhibiting c-JUN-driven pro-metastatic properties

Siche Chen, Jörg H. Leupold, Nitin S. Patil, Peiren Xu, Xinyu Wang, Xinye Hu, Heike Allgayer

10.1186/s12943-026-02703-9
View Publication

Multimodal sequencing identifies synergistic mechanisms driving resistance to neoadjuvant nivolumab treatment in hepatocellular carcinoma

Fanhong Zeng, Jiaxin Guo, Zheng Zeng, Vanilla Xin Zhang, Yu-Man Tsui, Po-Man Li, Abdullah Husain, Qingyang Zhang, Joyce Man-Fong Lee, Tan-To Cheung, Daniel Wai-Hung Ho, Irene Oi-Lin Ng

10.1186/s12943-026-02682-x
View Publication

Landscape of T-cell bispecific antibodies in cancer therapy: therapeutic strategies, challenges and future prospection

Guanda Jiao, Hongsen Peng, Yiqi Yang, Yang Liu, Xiaoxi Liu, Yuanjia Hu, Yeneng Dai, Zhoufang Li, Qi Zhao

10.1186/s12943-026-02685-8
View Publication

Multi-omic profiles of neuroendocrine neoplasms of the pancreas: an integrated landscape

Michele Bevere, Anastasios Gkountakos, Silvia Valentinuzzi, Simone De Fabritiis, Chee S. Wong, Riccardo De Robertis, Paola Mattiolo, Manuel Gentiluomo, Matteo Fassan, Antonio Pea, Stefano F. Crinò, Michele Simbolo, Andrea Mafficini, Daniele Campa, Sara Cingarlini, Luca Landoni, Rita T. Lawlor, Roberto Salvia, Mirko D’Onofrio, Michele Milella, Volkan Adsay, Lodewijk A. Brosens, Christopher M. Heaphy, Seung-Mo Hong, Aatur D. Singhi, Aldo Scarpa, Claudio Luchini

10.1186/s12943-026-02697-4
View Publication

Frequently asked questions

How long does it take to publish?

Submission to first decision (median): 3 days; less than 7 days time-to-first-decision.

Reformat to Molecular Cancer using Livewrite Premium

Is a cover letter required?

A cover letter is required. It should explain why the manuscript should be published in Molecular Cancer, address any issues relating to journal policies, declare potential competing interests, confirm all authors approved submission, confirm the work has not been published or submitted elsewhere, and mention the special issue name if applicable. Authors may also suggest preferred or non-preferred reviewers in the cover letter.

Reformat to Molecular Cancer using Livewrite Premium

What are the publication costs?

An article processing charge applies for each accepted article. The current APC is £3690.00 GBP / $5290.00 USD / €4390.00 EUR, plus VAT or local taxes where applicable.

Reformat to Molecular Cancer using Livewrite Premium

Research Topics

Cancer-related molecular mechanisms research MicroRNA in disease regulation Circular RNAs in diseases Cancer Cells and Metastasis RNA modifications and cancer Cancer, Hypoxia, and Metabolism Epigenetics and DNA Methylation Cancer Immunotherapy and Biomarkers Ferroptosis and cancer prognosis Cancer-related Molecular Pathways Immune cells in cancer Extracellular vesicles in disease Cell death mechanisms and regulation Cancer Genomics and Diagnostics Immunotherapy and Immune Responses Cancer-related gene regulation Wnt/β-catenin signaling in development and cancer Cancer Mechanisms and Therapy RNA Research and Splicing PI3K/AKT/mTOR signaling in cancer Ubiquitin and proteasome pathways Microtubule and mitosis dynamics Cytokine Signaling Pathways and Interactions Immune Cell Function and Interaction CAR-T cell therapy research

Related Journals

AS
Alzheimer s Research & Therapy BioMed Central
CO
Current Oncology Reports Springer Science+Business Media
JO
Journal of Translational Medicine BioMed Central
CB
Cancer Biology and Medicine Chinese Anti-Cancer Association
KS
Knee Surgery and Related Research BioMed Central
ER
European Review of Aging and Physical Activity BioMed Central